The goal of this article is to provide a new design framework and its corresponding estimation for phase I trials. Existing phase I designs assign each subject to one dose level based on responses from previous subjects. Yet it is possible that subjects with neither toxicity nor efficacy responses can be treated at higher dose levels, and their subsequent responses to higher doses will provide more information. In addition, for some trials, it might be possible to obtain multiple responses (repeated measures) from a subject at different dose levels. In this article, a nonparametric estimation method is developed for such studies. We also explore how the designs of multiple doses per subject can be implemented to improve design efficiency. T...
Summary. The use of multiple drugs in a single clinical trial or as a therapeutic strategy has becom...
Summary. The use of multiple drugs in a single clinical trial or as a therapeutic strategy has becom...
There is a growing medical interest in combining several agents and optimizing their dosing schedule...
The goal of this article is to provide a new design framework and its corresponding estimation for p...
The goal of this article is to provide a new design framework and its corresponding estimation for p...
This research examines new design approaches for Phase I clinical trials, which are designed to stud...
This research examines new design approaches for Phase I clinical trials, which are designed to stud...
In a dose-escalation trial for a new drug, each successive dose is tested on a new cohort of volunte...
Motivcrtion/Background: This paper addresses designing a Phase 1 trial where the dose-response curve...
Phase I-II cancer clinical trial designs are intended to accelerate drug development. In cases where...
Clinical trials are experiments tested on human to compare the effect of certain intervention. In ea...
Title from first page of PDF file (viewed January 11, 2011)Includes bibliographical references (p. 3...
UnrestrictedThe current designs of Phase I trials are comprehensively reviewed and classified by alg...
Dose-response experiments and subsequent data analyses are often carried out according to optimal de...
This chapter describes the main rule-based and model-based approaches for conducting phase I dose-es...
Summary. The use of multiple drugs in a single clinical trial or as a therapeutic strategy has becom...
Summary. The use of multiple drugs in a single clinical trial or as a therapeutic strategy has becom...
There is a growing medical interest in combining several agents and optimizing their dosing schedule...
The goal of this article is to provide a new design framework and its corresponding estimation for p...
The goal of this article is to provide a new design framework and its corresponding estimation for p...
This research examines new design approaches for Phase I clinical trials, which are designed to stud...
This research examines new design approaches for Phase I clinical trials, which are designed to stud...
In a dose-escalation trial for a new drug, each successive dose is tested on a new cohort of volunte...
Motivcrtion/Background: This paper addresses designing a Phase 1 trial where the dose-response curve...
Phase I-II cancer clinical trial designs are intended to accelerate drug development. In cases where...
Clinical trials are experiments tested on human to compare the effect of certain intervention. In ea...
Title from first page of PDF file (viewed January 11, 2011)Includes bibliographical references (p. 3...
UnrestrictedThe current designs of Phase I trials are comprehensively reviewed and classified by alg...
Dose-response experiments and subsequent data analyses are often carried out according to optimal de...
This chapter describes the main rule-based and model-based approaches for conducting phase I dose-es...
Summary. The use of multiple drugs in a single clinical trial or as a therapeutic strategy has becom...
Summary. The use of multiple drugs in a single clinical trial or as a therapeutic strategy has becom...
There is a growing medical interest in combining several agents and optimizing their dosing schedule...